CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Combination Product: Nivolumab with Pemetrexeddrug
Likely dose
Combination Product: Nivolumab with Pemetrexed 3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04107103
NCT04107103Phase 2Completed
CompareCT.gov

A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck

AHS Cancer Control Alberta·interventional·Posted Sep 27, 2019·Updated Jun 14, 2024

In Brief

A Phase 2 clinical trial evaluating Combination Product: Nivolumab with Pemetrexed for SCCHN. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to find out what effects the combination of Nivolumab and Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness of this treatment will be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSCCHN
CountriesCanada
CollaboratorsAlberta Cancer Foundation

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 27, 2019
Enrollment StartMar 19, 2020
Primary CompletionApr 14, 2023
Study CompletionApr 28, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.8 years ago

Interventions

Combination Product: Nivolumab with Pemetrexeddrug

Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly. Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days. Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.